Forte Biosciences Inc (FBRX) Form 4 Filed by Barbara K Finck, Aug 27, 2026
SEC Form 4 · No Market Transaction
Return To Issuer
Non-market transaction reported.
Filing Lag
0 business days
within 2-day SEC deadline
Form 4 · Statement of Changes in Beneficial Ownership
Reporting Owner
| Name | Relationship |
|---|---|
| Barbara K Finck CIK 0001242116 |
Director
|
Barbara K Finck at Forte Biosciences Inc
Full insider history
Bought (12 mo)
—
Sold (12 mo)
—
More from this insider at Forte Biosciences Inc
| 2025-03-21 | Award | — | View |
| 2024-08-22 | Award | — | View |
| 2024-03-25 | Award | — | View |
| 2023-09-20 | Award | — | View |
| 2022-06-02 | Award | — | View |
Derivative Securities Transactions
| Title | Strike | Date | Type | Shares | Price | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1F2 | $35.75 | 2026-08-27 | D - Return to Issuer | 2,000 D | 2032-03-16 | 2,000 Common Stock | Direct | |
| Stock Option (right to buy)F1F2 | $31.75 | 2026-08-27 | D - Return to Issuer | 1,000 D | 2032-06-01 | 1,000 Common Stock | Direct | |
| Stock Option (right to buy)F1F2 | $20.00 | 2026-08-27 | D - Return to Issuer | 1,000 D | 2033-09-19 | 1,000 Common Stock | Direct | |
| Stock Option (right to buy)F1F2F1F2 | $17.25 | 2026-08-27 | D - Return to Issuer | 7,000 D | 2034-03-21 | 7,000 Common Stock | Direct | |
| Stock Option (right to buy)F1F2F1F2 | $7.02 | 2026-08-27 | D - Return to Issuer | 31,000 D | 2035-03-19 | 31,000 Common Stock | Direct | |
| Stock Option (right to buy)]F1F2 | $35.75 | 2026-08-27 | D - Return to Issuer | 166 D | 2032-03-16 | 166 Common Stock | Direct | |
| Restricted Stock UnitsF3F4F4F4 | 2026-08-27 | D - Return to Issuer | 18,353 D | 18,353 Common Stock | Direct |
Footnotes (4)
- F1
- Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent. Show more
- F2
- At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor. Show more
- F3
- Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock. Show more
- F4
- Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger. Show more
Related filings at Forte Biosciences Inc
Institutional Holders
13F holders · Jun 30, 2026
86
institutional managers reporting a position
Largest by reported value
- Federated Hermes, Inc. $44.8M
- Orbimed Advisors Llc $33.5M
- Fred Alger Management, Llc $30.6M
5%+ Holders · 13D/G
7 filers
-
Orbimed Advisors Llc 6.2%
-
Glazer Capital, Llc 1.5%
-
Black Rock, Inc. 5.9%
Other insiders at Forte Biosciences Inc
GET /v1/forms/4/0001242116-26-000001
API docs
View Original SEC Filing